Campbell & Co Investment Adviser’s Ocular Therapeutix OCUL Stock Holding History

Campbell & Co Investment Adviser’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$306K	Buy	+31,135	New	+$282K	0.02%	896
2026 Q1	–	Sell	-119,285	Closed	-$1.45M	–	1319
2025 Q4	$1.45M	Buy	119,285 +108,022	+959%	+$1.31M	0.07%	433
2025 Q3	$132K	Buy	+11,263	New	+$135K	0.01%	1034
2025 Q1	–	Sell	-12,071	Closed	-$103K	–	1242
2024 Q4	$103K	Buy	+12,071	New	+$118K	0.01%	1009
2024 Q2	–	Sell	-12,537	Closed	-$114K	–	1268
2024 Q1	$114K	Buy	+12,537	New	+$89K	0.01%	1059
2022 Q1	–	Sell	-18,200	Closed	-$127K	–	839
2021 Q4	$127K	Buy	+18,200	New	+$141K	0.04%	573

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Campbell & Co Investment Adviser's OCUL Position: Q2 2026 in Review

Campbell & Co Investment Adviser opened a new position in Ocular Therapeutix (OCUL) in Q2 2026: 31,135 shares worth $306K. The stake represents 0.02% of the portfolio and ranks #896 among its holdings. This is a return to the name: Campbell & Co Investment Adviser previously reported a position in OCUL as recently as Q4 2025.

Campbell & Co Investment Adviser first reported a position in OCUL in Q4 2021 and has held it in 6 quarters since. The position peaked at $1.45M in Q4 2025. 262 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

Campbell & Co Investment Adviser held 31,135 shares of Ocular Therapeutix worth $306K as of Q2 2026.
Ocular Therapeutix was a new Campbell & Co Investment Adviser position in Q2 2026.
Ocular Therapeutix made up 0.02% of Campbell & Co Investment Adviser's portfolio in Q2 2026, its #896 holding.
Campbell & Co Investment Adviser first reported a position in Ocular Therapeutix in Q4 2021 and has held it in 6 quarters since.
Campbell & Co Investment Adviser's Ocular Therapeutix position peaked at $1.45M in Q4 2025.
262 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q2 2026, filed 3 Aug 2026.